Systemic corticosteroids for community-acquired pneumonia: Reasons for use and lack of benefit on outcome

Respirology

Volumn 18, Issue 2, 2013, Pages 263-271

  Polverino, Eva ^a   Cillóniz, Catia ^a   Dambrava, Povilas ^b   Gabarrús, Albert ^a   Ferrer, Miquel ^a   Agustí, Carlos ^a   Prina, Elena ^d   Montull, Beatriz ^c   Menendez, Rosario ^c   Niederman, Michael S ^e,f   Torres, Antoni ^a  

^a HOSPITAL CLÍNIC   (Spain)

^b Respiratory and Sleep Disorders Unit   (Spain)

^c HOSPITAL UNIVERSITARIO LA FE   (Spain)

^d UNIVERSITY OF MILAN   (Italy)

^e WINTHROP UNIVERSITY HOSPITAL   (United States)

^f STONY BROOK UNIVERSITY   (United States)

Author keywords

adjunctive therapy; clinical stability; community acquired pneumonia; mortality; systemic corticosteroid

Indexed keywords

ANTIBIOTIC AGENT; C REACTIVE PROTEIN; CREATININE; METHYLPREDNISOLONE;

AGED; ANTIBIOTIC THERAPY; ARTICLE; CHRONIC OBSTRUCTIVE LUNG DISEASE; COMMUNITY ACQUIRED PNEUMONIA; COMORBIDITY; CORTICOSTEROID THERAPY; FEMALE; FEVER; HEART FAILURE; HUMAN; LENGTH OF STAY; MAJOR CLINICAL STUDY; MALE; MORTALITY; OBSERVATIONAL STUDY; PNEUMONIA SEVERITY INDEX; PRIORITY JOURNAL; PROSPECTIVE STUDY; SPUTUM; SYSTEMIC THERAPY; TREATMENT OUTCOME;

ADRENAL CORTEX HORMONES; AGED; AGED, 80 AND OVER; COMMUNITY-ACQUIRED INFECTIONS; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; HUMANS; LENGTH OF STAY; MALE; MIDDLE AGED; PNEUMONIA; RETROSPECTIVE STUDIES; SEVERITY OF ILLNESS INDEX; SURVIVAL RATE; TREATMENT OUTCOME;

EID: 84872896068     PISSN: 13237799     EISSN: 14401843     Source Type: Journal    
DOI: 10.1111/resp.12013     Document Type: Article

References (26)

1. Monton C, Ewig S, Torres A, et al. Role of glucocorticoids on inflammatory response in nonimmunosuppressed patients with pneumonia: A pilot study. Eur. Respir. J. 1999; 14: 218-220. (Pubitemid 29411261)
2. Confalonieri M, Urbino R, Potena A, et al. Hydrocortisone infusion for severe community-acquired pneumonia: A preliminary randomized study. Am. J. Respir. Crit. Care Med. 2005; 171: 242-248.
3. Garcia-Vidal C, Calbo E, Pascual V, et al. Effects of systemic steroids in patients with severe community-acquired pneumonia. Eur. Respir. J. 2007; 30: 951-956. (Pubitemid 351194800)
4. Meijvis SC, Hardeman H, Remmelts HH, et al. Dexamethasone and length of hospital stay in patients with community-acquired pneumonia: A randomised, double-blind, placebo-controlled trial. Lancet 2011; 377: 2023-2030.
5. Mikami K, Suzuki M, Kitagawa H, et al. Efficacy of corticosteroids in the treatment of community-acquired pneumonia requiring hospitalization. Lung 2007; 185: 249-255. (Pubitemid 47397487)
6. Fernandez-Serrano S, Dorca J, Garcia-Vidal C, et al. Effect of corticosteroids on the clinical course of community-acquired pneumonia: A randomized controlled trial. Crit. Care 2011; 15: R96.
7. Marik P, Kraus P, Sribante J, et al. Hydrocortisone and tumor necrosis factor in severe community-acquired pneumonia. A randomized controlled study. Chest 1993; 104: 389-392. (Pubitemid 23229504)
8. Snijders D, Daniels JM, de, Graaff CS, et al. Efficacy of corticosteroids in community-acquired pneumonia: A randomized double-blinded clinical trial. Am. J. Respir. Crit. Care Med. 2010; 181: 975-982.
9. Salluh JI, Povoa P, Soares M, et al. The role of corticosteroids in severe community-acquired pneumonia: A systematic review. Crit. Care 2008; 12: R76.
10. Lim WS, Baudouin SV, George RC, et al. BTS guidelines for the management of community acquired pneumonia in adults: update 2009. Thorax 2009; 64 (Suppl. 3): iii1-55.
11. Fine MJ, Auble TE, Yealy DM, et al. A prediction rule to identify low-risk patients with community-acquired pneumonia. N. Engl. J. Med. 1997; 336: 243-250. (Pubitemid 27044625)
12. Lim WS, van der Eerden MM, Laing R, et al. Defining community acquired pneumonia severity on presentation to hospital: an international derivation and validation study. Thorax 2003; 58: 377-382. (Pubitemid 36560938)
13. Sibila O, Luna CM, Agusti C, et al. Effects of glucocorticoids in ventilated piglets with severe pneumonia. Eur. Respir. J. 2008; 32: 1037-1046.
14. Menendez R, Cavalcanti M, Reyes S, et al. Markers of treatment failure in hospitalised community acquired pneumonia. Thorax 2008; 63: 447-452. (Pubitemid 351692355)
15. Menendez R, Martinez R, Reyes S, et al. Biomarkers improve mortality prediction by prognostic scales in community-acquired pneumonia. Thorax 2009; 64: 587-591.
16. Martinez R, Menendez R, Reyes S, et al. Factors associated with inflammatory cytokine patterns in community-acquired pneumonia. Eur. Respir. J. 2011; 37: 393-399.
17. Mandell LA, Wunderink RG, Anzueto A, et al. Infectious Diseases Society of America/American Thoracic Society consensus guidelines on the management of community-acquired pneumonia in adults. Clin. Infect. Dis. 2007; 44 (Suppl. 2): S27-S72. (Pubitemid 46290553)
18. Salluh JI, Soares M, Coelho LM, et al. Impact of systemic corticosteroids on the clinical course and outcomes of patients with severe community-acquired pneumonia: A cohort study. J. Crit. Care 2011; 26: 193-200.
19. Gutierrez P, Closa D, Piner R, et al. Macrophage activation in exacerbated chronic obstructive pulmonary disease with and without community-acquired pneumonia. Eur. Respir. J. 2010; 36: 285-291.
20. Malo de Molina R, Mortensen EM, Restrepo MI, et al. Inhaled corticosteroid use is associated with lower mortality for subjects with COPD and hospitalised with pneumonia. Eur. Respir. J. 2010; 36: 751-757.
21. Chen D, Restrepo MI, Fine MJ, et al. Observational study of inhaled corticosteroids on outcomes for COPD patients with pneumonia. Am. J. Respir. Crit. Care Med. 2011; 184: 312-316.
22. Calverley PM, Anderson JA, Celli B, et al. Salmeterol and fluticasone propionate and survival in chronic obstructive pulmonary disease. N. Engl. J. Med. 2007; 356: 775-789. (Pubitemid 46294610)
23. Drummond MB, Dasenbrook EC, Pitz MW, et al. Inhaled corticosteroids in patients with stable chronic obstructive pulmonary disease: A systematic review and meta-analysis. JAMA 2008; 300: 2407-2416.
24. Ruiz M, Ewig S, Torres A, et al. Severe community-acquired pneumonia. Risk factors and follow-up epidemiology. Am. J. Respir. Crit. Care Med. 1999; 160: 923-929. (Pubitemid 29442032)
25. Menendez R, Torres A, Rodriguez CF, et al. Reaching stability in community-acquired pneumonia: the effects of the severity of disease, treatment, and the characteristics of patients. Clin. Infect. Dis. 2004; 39: 1783-1790. (Pubitemid 39657257)
26. Johnson D, Carriere KC, Jin Y, et al. Appropriate antibiotic utilization in seniors prior to hospitalization for community-acquired pneumonia is associated with decreased in-hospital mortality. J. Clin. Pharm. Ther. 2004; 29: 231-239. (Pubitemid 38901534)